SG11201804664XA - Salt forms and polymorphs of (r)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl) acetamido) pyridazin-3-yl)-2-fluorobutyl)-n-methyl-1h-1,2,3-triazole-4-carboxamide - Google Patents
Salt forms and polymorphs of (r)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl) acetamido) pyridazin-3-yl)-2-fluorobutyl)-n-methyl-1h-1,2,3-triazole-4-carboxamideInfo
- Publication number
- SG11201804664XA SG11201804664XA SG11201804664XA SG11201804664XA SG11201804664XA SG 11201804664X A SG11201804664X A SG 11201804664XA SG 11201804664X A SG11201804664X A SG 11201804664XA SG 11201804664X A SG11201804664X A SG 11201804664XA SG 11201804664X A SG11201804664X A SG 11201804664XA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- difluorocyclobutoxy
- pyridazin
- polymorphs
- acetamido
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562271018P | 2015-12-22 | 2015-12-22 | |
| PCT/US2016/068149 WO2017112831A1 (en) | 2015-12-22 | 2016-12-21 | Salt forms and polymorphs of (r)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl) acetamido) pyridazin-3-yl)-2-fluorobutyl)-n-methyl-1h-1,2,3-triazole-4-carboxamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201804664XA true SG11201804664XA (en) | 2018-07-30 |
Family
ID=59065954
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201804664XA SG11201804664XA (en) | 2015-12-22 | 2016-12-21 | Salt forms and polymorphs of (r)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl) acetamido) pyridazin-3-yl)-2-fluorobutyl)-n-methyl-1h-1,2,3-triazole-4-carboxamide |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US10150753B2 (ja) |
| EP (1) | EP3394039A4 (ja) |
| JP (1) | JP6976248B2 (ja) |
| KR (1) | KR20180095677A (ja) |
| CN (1) | CN108602782B (ja) |
| AU (1) | AU2016378746B2 (ja) |
| BR (1) | BR112018012660B1 (ja) |
| CA (1) | CA3009355A1 (ja) |
| IL (1) | IL260178B2 (ja) |
| MX (1) | MX2018007143A (ja) |
| RU (1) | RU2018124266A (ja) |
| SG (1) | SG11201804664XA (ja) |
| WO (1) | WO2017112831A1 (ja) |
| ZA (1) | ZA201804843B (ja) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3164394T (pt) | 2014-07-03 | 2020-05-08 | Univ Texas | Inibidores gls1 para o tratamento de doenças |
| WO2017004359A1 (en) | 2015-06-30 | 2017-01-05 | Board Of Regents, University Of Texas System | Gls1 inhibitors for treating disease |
| US10150753B2 (en) | 2015-12-22 | 2018-12-11 | Board Of Regents, The University Of Texas System | Salt forms and polymorphs of (R)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyrdin-2-yl)acetamido) pyridazin-3-yl)-2-fluorobutyl)-N-methyl-1H-1,2,3-triazole-4-carboxamide |
| RU2020112558A (ru) | 2017-10-18 | 2021-11-18 | Боард Оф Регентс, Зе Юниверсити Оф Тексас Систем | Терапия на основе ингибитора глутаминазы |
| CN116023375A (zh) * | 2021-10-25 | 2023-04-28 | 成都苑东生物制药股份有限公司 | 一种杂环类衍生物、其制备方法及用途 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES498337A0 (es) | 1980-01-07 | 1982-06-01 | Nyegaard & Co As | Un procedimiento para la preparacion de 5-halo-pirimidin-2- onas |
| DE3572230D1 (en) | 1985-10-10 | 1989-09-14 | Agfa Gevaert Nv | Image-recieving element for the silver salt diffusion transfer reversal process |
| WO1991009848A1 (en) | 1989-12-22 | 1991-07-11 | The Upjohn Company | Pyridinones useful as antiatherosclerotic agents |
| IL118325A0 (en) | 1995-05-25 | 1996-10-31 | Pont Merck And Pharmaceutical | Integrin receptor antagonists and pharmaceutical compositions containing them |
| ATE278399T1 (de) | 1995-07-21 | 2004-10-15 | Savvipharm Inc | Orotatsalze von 5-amino- oder substituierten amino-1,2,3-triazolen zur behandlung von neoplasmen |
| AU6780398A (en) | 1997-03-28 | 1998-10-22 | Du Pont Merck Pharmaceutical Company, The | Heterocyclic integrin inhibitor prodrugs |
| CA2309204A1 (en) | 1997-11-26 | 1999-06-03 | Dupont Pharmaceuticals Company | 1,3,4-thiadiazoles and 1,3,4-oxadiazoles as .alpha.v.beta.3 antagonists |
| US6451828B1 (en) | 2000-08-10 | 2002-09-17 | Elan Pharmaceuticals, Inc. | Selective inhibition of glutaminase by bis-thiadiazoles |
| SE0400208D0 (sv) | 2004-02-02 | 2004-02-02 | Astrazeneca Ab | Chemical compounds |
| US7985548B2 (en) | 2006-03-03 | 2011-07-26 | The United States Of America As Represented By The Department Of Health And Human Services | Materials and methods directed to asparagine synthetase and asparaginase therapies |
| US7638541B2 (en) | 2006-12-28 | 2009-12-29 | Metabolex Inc. | 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
| CA2686933A1 (en) | 2007-04-06 | 2008-10-16 | The Johns Hopkins University | Methods and compositions for the treatment of cancer |
| AU2009218607B2 (en) | 2008-02-25 | 2014-02-13 | F. Hoffmann-La Roche Ag | Pyrrolopyrazine kinase inhibitors |
| HUE035029T2 (en) | 2008-05-21 | 2018-03-28 | Ariad Pharma Inc | Kinase inhibitor phosphorus derivatives |
| JP2011231015A (ja) | 2008-08-29 | 2011-11-17 | Taiho Yakuhin Kogyo Kk | 含窒素複素環を有する新規ウラシル化合物又はその塩 |
| MX2011008982A (es) | 2009-02-27 | 2011-09-15 | Enata Pharmaceuticals Inc | Inhibidores del virus de la hepatitis c. |
| US10532034B2 (en) | 2009-03-25 | 2020-01-14 | Cornell University | Inhibition of glutaminase C |
| JP5725475B2 (ja) | 2010-01-21 | 2015-05-27 | 公立大学法人名古屋市立大学 | ヒドロキサム酸誘導体及びそれを用いたｈｄａｃ８阻害剤 |
| US20130109643A1 (en) | 2010-05-10 | 2013-05-02 | The Johns Hopkins University | Metabolic inhibitor against tumors having an idh mutation |
| EA026656B1 (ru) | 2011-11-21 | 2017-05-31 | Калитера Байосайенсиз Инк. | Гетероциклические ингибиторы глютаминазы |
| US8604016B2 (en) | 2011-11-21 | 2013-12-10 | Calithera Biosciences Inc. | Heterocyclic inhibitors of glutaminase |
| DK2920168T3 (da) | 2012-11-16 | 2021-10-18 | Calithera Biosciences Inc | Heterocykliske glutaminase-inhibitorer |
| AU2013347933C1 (en) | 2012-11-21 | 2018-10-04 | Agios Pharmaceuticals, Inc. | Glutaminase inhibitors and methods of use |
| WO2014079011A1 (en) | 2012-11-22 | 2014-05-30 | Agios Pharmaceuticals, Inc. | Heterocyclic compounds for inhibiting glutaminase and their methods of use |
| US9029531B2 (en) | 2012-11-22 | 2015-05-12 | Agios Pharmaceuticals, Inc. | Compounds and their methods of use |
| SG11201504184PA (en) * | 2012-12-03 | 2015-06-29 | Calithera Biosciences Inc | Treatment of cancer with heterocyclic inhibitors of glutaminase |
| CN104955332B (zh) | 2013-01-30 | 2017-03-29 | 住友化学株式会社 | 防治节足害虫的方法 |
| TW201500356A (zh) | 2013-04-12 | 2015-01-01 | Lilly Co Eli | 二氫吡啶并嘧啶化合物 |
| DK3092236T3 (en) | 2014-01-06 | 2020-11-30 | Rhizen Pharmaceuticals S A | Nye glutaminaseinhibitorer |
| US20160058759A1 (en) | 2014-07-03 | 2016-03-03 | Board Of Regents, The University Of Texas System | Glutaminase inhibitor therapy |
| WO2016004418A1 (en) | 2014-07-03 | 2016-01-07 | Board Of Regents, University Of Texas System | Glutaminase inhibitor therapy |
| US20160002248A1 (en) | 2014-07-03 | 2016-01-07 | Board Of Regents, The University Of Texas System | Gls1 inhibitors for treating disease |
| PT3164394T (pt) * | 2014-07-03 | 2020-05-08 | Univ Texas | Inibidores gls1 para o tratamento de doenças |
| US20160002204A1 (en) | 2014-07-03 | 2016-01-07 | Board Of Regents, The University Of Texas System | Gls1 inhibitors for treating disease |
| WO2017004359A1 (en) | 2015-06-30 | 2017-01-05 | Board Of Regents, University Of Texas System | Gls1 inhibitors for treating disease |
| US10150753B2 (en) | 2015-12-22 | 2018-12-11 | Board Of Regents, The University Of Texas System | Salt forms and polymorphs of (R)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyrdin-2-yl)acetamido) pyridazin-3-yl)-2-fluorobutyl)-N-methyl-1H-1,2,3-triazole-4-carboxamide |
| RU2020112558A (ru) | 2017-10-18 | 2021-11-18 | Боард Оф Регентс, Зе Юниверсити Оф Тексас Систем | Терапия на основе ингибитора глутаминазы |
-
2016
- 2016-12-21 US US15/387,560 patent/US10150753B2/en active Active
- 2016-12-21 JP JP2018526554A patent/JP6976248B2/ja active Active
- 2016-12-21 AU AU2016378746A patent/AU2016378746B2/en active Active
- 2016-12-21 BR BR112018012660-8A patent/BR112018012660B1/pt active IP Right Grant
- 2016-12-21 SG SG11201804664XA patent/SG11201804664XA/en unknown
- 2016-12-21 WO PCT/US2016/068149 patent/WO2017112831A1/en active Application Filing
- 2016-12-21 CA CA3009355A patent/CA3009355A1/en active Pending
- 2016-12-21 EP EP16880068.8A patent/EP3394039A4/en active Pending
- 2016-12-21 RU RU2018124266A patent/RU2018124266A/ru unknown
- 2016-12-21 CN CN201680075353.5A patent/CN108602782B/zh active Active
- 2016-12-21 MX MX2018007143A patent/MX2018007143A/es unknown
- 2016-12-21 KR KR1020187020755A patent/KR20180095677A/ko not_active Application Discontinuation
-
2018
- 2018-06-20 IL IL260178A patent/IL260178B2/en unknown
- 2018-07-18 ZA ZA2018/04843A patent/ZA201804843B/en unknown
-
2019
- 2019-01-07 US US16/241,596 patent/US10899740B2/en active Active
-
2020
- 2020-12-16 US US17/124,051 patent/US11603365B2/en active Active
-
2023
- 2023-02-01 US US18/163,151 patent/US20230250081A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016378746A1 (en) | 2018-06-28 |
| KR20180095677A (ko) | 2018-08-27 |
| US11603365B2 (en) | 2023-03-14 |
| US10150753B2 (en) | 2018-12-11 |
| BR112018012660B1 (pt) | 2023-12-19 |
| US20170174661A1 (en) | 2017-06-22 |
| JP2019502663A (ja) | 2019-01-31 |
| WO2017112831A1 (en) | 2017-06-29 |
| JP6976248B2 (ja) | 2021-12-08 |
| EP3394039A1 (en) | 2018-10-31 |
| RU2018124266A3 (ja) | 2020-03-25 |
| EP3394039A4 (en) | 2019-06-12 |
| BR112018012660A2 (pt) | 2018-12-04 |
| CA3009355A1 (en) | 2017-06-29 |
| IL260178B2 (en) | 2023-05-01 |
| CN108602782A (zh) | 2018-09-28 |
| RU2018124266A (ru) | 2020-01-23 |
| AU2016378746B2 (en) | 2021-05-20 |
| IL260178B1 (en) | 2023-01-01 |
| US20210206745A1 (en) | 2021-07-08 |
| CN108602782B (zh) | 2022-06-17 |
| IL260178A (en) | 2018-07-31 |
| US20230250081A1 (en) | 2023-08-10 |
| US20190144425A1 (en) | 2019-05-16 |
| US10899740B2 (en) | 2021-01-26 |
| MX2018007143A (es) | 2018-11-29 |
| ZA201804843B (en) | 2019-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201804664XA (en) | Salt forms and polymorphs of (r)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl) acetamido) pyridazin-3-yl)-2-fluorobutyl)-n-methyl-1h-1,2,3-triazole-4-carboxamide | |
| SG11201810983PA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201909155VA (en) | Ask1 inhibitor compounds and uses thereof | |
| SG11201809714TA (en) | Piperidines as menin inhibitors | |
| SG11201804758QA (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
| SG11201804132UA (en) | Eif4-a-inhibiting compounds and methods related thereto | |
| SG11201811225RA (en) | Ar+ breast cancer treatment methods | |
| SG11201808125RA (en) | Methods for solid tumor treatment | |
| SG11201909561RA (en) | Octree-based convolutional neural network | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201900405XA (en) | Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia | |
| SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
| SG11201808762XA (en) | Diagnostic methods for patient specific therapeutic decision making in cancer care | |
| SG11201805204WA (en) | Nicotine particle capsule | |
| SG11201804774YA (en) | Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031 | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201805777QA (en) | Formulations of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide | |
| SG11201805385QA (en) | Bromodomain and extra-terminal protein inhibitor combination therapy | |
| SG11201811686UA (en) | 18f-labeled triazole containing psma inhibitors | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
| SG11201804291XA (en) | An elastic core composite or assembly, and a system and method for making the elastic composite assembly | |
| SG11201809223PA (en) | Erbb inhibitors and uses thereof |